TY - JOUR
T1 - Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: Parallel study of 81 patients
AU - Xicoy, Blanca
AU - Ribera, Josep Maria
AU - Müller, Markus
AU - García, Olga
AU - Hoffmann, Christian
AU - Oriol, Albert
AU - Hentrich, Marcus
AU - Grande, Carlos
AU - Wasmuth, Jan Christian
AU - Esteve, Jordi
AU - Van Lunzen, Jan
AU - Del Potro, Eloy
AU - Knechten, Heribert
AU - Brunet, Salut
AU - Mayr, Christoph
AU - Escoda, Lourdes
AU - Schommers, Philipp
AU - Alonso, Natalia
AU - Vall-Llovera, Ferran
AU - Pérez, Montserrat
AU - Morgades, Mireia
AU - González, José
AU - Fernández, Angeles
AU - Thoden, Jan
AU - Gökbuget, Nicola
AU - Hoelzer, Dieter
AU - Fätkenheuer, Gerd
AU - Wyen, Christoph
PY - 2014/10/1
Y1 - 2014/10/1
N2 - © 2014 Informa UK, Ltd. The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for patients over 55 years. Eighty percent of patients achieved remission, 11% died during induction, 9% failed and 7% died in remission. Four-year overall survival (OS) and progression-free survival (PFS) probabilities were 72% (95% confidence interval [CI]: 62-82%) and 71% (95% CI: 61-81%). CD4 T-cell count < 200/μL and bone marrow involvement were associated with poor OS (hazard ratio [HR] 3.2 [1.2-8.3] and HR 2.7 [1.1-6.6]) and PFS (HR 3.5 [1.3-9.1] and HR 2.4 [1-5.7]), bone marrow involvement with poor disease-free survival (DFS) (HR 14.4 [1.7-119.7] and Eastern Cooperative Oncology Group (ECOG) score > 2 (odds ratio [OR] 11.9 [1.4-99.9]) with induction death. In HIV-related BLL, intensive immunochemotherapy was feasible and effective, but toxic. Prognostic factors were performance status, CD4 T-cell count and bone marrow involvement.
AB - © 2014 Informa UK, Ltd. The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for patients over 55 years. Eighty percent of patients achieved remission, 11% died during induction, 9% failed and 7% died in remission. Four-year overall survival (OS) and progression-free survival (PFS) probabilities were 72% (95% confidence interval [CI]: 62-82%) and 71% (95% CI: 61-81%). CD4 T-cell count < 200/μL and bone marrow involvement were associated with poor OS (hazard ratio [HR] 3.2 [1.2-8.3] and HR 2.7 [1.1-6.6]) and PFS (HR 3.5 [1.3-9.1] and HR 2.4 [1-5.7]), bone marrow involvement with poor disease-free survival (DFS) (HR 14.4 [1.7-119.7] and Eastern Cooperative Oncology Group (ECOG) score > 2 (odds ratio [OR] 11.9 [1.4-99.9]) with induction death. In HIV-related BLL, intensive immunochemotherapy was feasible and effective, but toxic. Prognostic factors were performance status, CD4 T-cell count and bone marrow involvement.
KW - Burkitt lymphoma or leukemia
KW - HIV infection
KW - Prognostic factors
KW - Specific chemotherapy
U2 - 10.3109/10428194.2013.878933
DO - 10.3109/10428194.2013.878933
M3 - Article
SN - 1042-8194
VL - 55
SP - 2341
EP - 2348
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -
